Lilly Drug to Change Squamous NSCLC, but ODAC's Opinion is Nuanced

The FDA Oncologic Drugs Advisory Committee July 9 appears to have recommended approval for the Eli Lilly and Co. agent necitumumab.Yes, the word “appears” has indeed appeared in the previous sentence.